Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Talitha L Feenstra

Showing results (71-80 of 76) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 76 results.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 17, 2014
Cost-effectiveness models for chronic obstructive pulmonary disease: cross-model comparison of hypothetical treatment scenariosMartine Hoogendoorn, Talitha L Feenstra, Yumi Asukai, et al.
Nederlands Tijdschrift Voor Geneeskunde|November 14, 2013
[Societal costs of asthma, COPD and respiratory allergy]Anita W M Suijkerbuijk, G A Ardine de Wit, Alet H Wijga, et al.
Diabetologia|April 5, 2020
Prediction models for development of retinopathy in people with type 2 diabetes: systematic review and external validation in a Dutch primary care settingAmber A van der Heijden, Giel Nijpels, Fariza Badloe, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|October 8, 2016
Patient Heterogeneity in Health Economic Decision Models for Chronic Obstructive Pulmonary Disease: Are Current Models Suitable to Evaluate Personalized Medicine?Martine Hoogendoorn, Talitha L Feenstra, Yumi Asukai, et al.
BMJ (Clinical Research Ed.)|September 29, 2021
Performance of prediction models for nephropathy in people with type 2 diabetes: systematic review and external validation studyRoderick C Slieker, Amber A W A van der Heijden, Moneeza K Siddiqui, et al.
Plos One|May 11, 2019
A social cost-benefit analysis of two One Health interventions to prevent toxoplasmosisAnita W M Suijkerbuijk, Eelco A B Over, Marieke Opsteegh, et al.
Pageof 8

Showing results (71-80 of 76) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 76 results.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 17, 2014
Cost-effectiveness models for chronic obstructive pulmonary disease: cross-model comparison of hypothetical treatment scenariosMartine Hoogendoorn, Talitha L Feenstra, Yumi Asukai, et al.
Nederlands Tijdschrift Voor Geneeskunde|November 14, 2013
[Societal costs of asthma, COPD and respiratory allergy]Anita W M Suijkerbuijk, G A Ardine de Wit, Alet H Wijga, et al.
Diabetologia|April 5, 2020
Prediction models for development of retinopathy in people with type 2 diabetes: systematic review and external validation in a Dutch primary care settingAmber A van der Heijden, Giel Nijpels, Fariza Badloe, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|October 8, 2016
Patient Heterogeneity in Health Economic Decision Models for Chronic Obstructive Pulmonary Disease: Are Current Models Suitable to Evaluate Personalized Medicine?Martine Hoogendoorn, Talitha L Feenstra, Yumi Asukai, et al.
BMJ (Clinical Research Ed.)|September 29, 2021
Performance of prediction models for nephropathy in people with type 2 diabetes: systematic review and external validation studyRoderick C Slieker, Amber A W A van der Heijden, Moneeza K Siddiqui, et al.
Plos One|May 11, 2019
A social cost-benefit analysis of two One Health interventions to prevent toxoplasmosisAnita W M Suijkerbuijk, Eelco A B Over, Marieke Opsteegh, et al.
Pageof 8